Abstract | BACKGROUND: METHODS: The efficacy, safety, and pharmacokinetics of lapatinib 750 mg given twice daily to Japanese HER2-overexpressing MBC patients with brain metastases were assessed as part of the international clinical study. RESULTS: Of six Japanese patients treated in this study, two patients had shown volumetric reduction >20 % in their central nervous system (CNS), one of whom had >50 % reduction. Three patients, including two of these patients, had shown >20 % volumetric reduction in non-CNS lesions. Frequently reported adverse events were diarrhea and rash, all of which were controllable. The AUC0-12 of lapatinib on day 28 was 1.74 times higher than that on day 1. CONCLUSION: These results suggest that lapatinib monotherapy 750 mg given twice daily can exert some efficacy and has potential as a clinically meaningful treatment option for Japanese HER2-overexpressing breast cancer patients with brain metastases after cranial radiation.
|
Authors | Hiroji Iwata, Masaru Narabayashi, Yoshinori Ito, Shigehira Saji, Yasuhiro Fujiwara, Shigeyuki Usami, Koichi Katsura, Yasutsuna Sasaki |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 18
Issue 4
Pg. 621-8
(Aug 2013)
ISSN: 1437-7772 [Electronic] Japan |
PMID | 23011099
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Quinazolines
- Lapatinib
- ERBB2 protein, human
- Receptor, ErbB-2
- Trastuzumab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Area Under Curve
- Asian People
- Brain Neoplasms
(drug therapy, radiotherapy, secondary)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Cranial Irradiation
- Drug Administration Schedule
- Female
- Humans
- Lapatinib
- Middle Aged
- Quinazolines
(administration & dosage, blood, pharmacokinetics, therapeutic use)
- Receptor, ErbB-2
(metabolism)
- Trastuzumab
- Treatment Outcome
|